We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-13.19%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.78B
AUM Growth
+$18.3M
Cap. Flow
+$336M
Cap. Flow %
12.09%
Top 10 Hldgs %
42.27%
Holding
179
New
61
Increased
32
Reduced
13
Closed
19

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$37.6M
2
UNH icon
UnitedHealth
UNH
+$37.4M
3
UTHR icon
United Therapeutics
UTHR
+$29.3M
4
MRK icon
Merck
MRK
+$27.6M
5
A icon
Agilent Technologies
A
+$24.1M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$27.7M
2
CELG
Celgene Corp
CELG
+$26.8M
3
CTRX
CATAMARAN CORP COM STK (CDA)
CTRX
+$26.5M
4
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$23.7M
5
ACOR
Acorda Therapeutics
ACOR
+$22.7M

Sector Composition

Rank Sector Weight
1 Healthcare 84.85%
2 Miscellaneous 10.25%
3 Real Estate 3.57%
4 Financials 1.31%
5 Technology 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLUE
76
DELISTED
bluebird bio
BLUE
$8.04M 0.29%
7,253
+4,096
+130% +$7.47M
ANAC
77
CALL
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$7.7M 0.28%
+65,400
New +$8.54M
ANAC
78
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$7.7M 0.28%
+65,400
New +$8.54M
WCG
79
DELISTED
Wellcare Health Plans, Inc.
WCG
$7.64M 0.27%
88,652
– –
CYTO
80
DELISTED
Altamira Therapeutics Ltd
CYTO
$7.5M 0.27%
26
– –
JUNO
81
DELISTED
Juno Therapeutics, Inc.
JUNO
$7.41M 0.27%
+182,000
New +$7.98M
MACK
82
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$7.27M 0.26%
108,516
+36,350
+50% +$2.97M
PBYI icon
83
Puma Biotechnology
PBYI
$477M
$7.17M 0.26%
+95,200
New +$9M
LLY icon
84
Eli Lilly
LLY
$1.01T
$7.17M 0.26%
+85,667
New +$7.23M
PVLA
85
Palvella Therapeutics
PVLA
$2.18B
$7.04M 0.25%
48,102
– –
ELGX
86
DELISTED
Endologix Inc
ELGX
$6.75M 0.24%
55,100
– –
DVAX
87
DELISTED
Dynavax Technologies
DVAX
$6.75M 0.24%
+275,000
New +$7.79M
CNC icon
88
Centene
CNC
$33.4B
$6.51M 0.23%
240,000
– –
SGNT
89
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
$6.28M 0.23%
409,500
– –
THC icon
90
Tenet Healthcare
THC
$21B
$6.07M 0.22%
164,500
– –
ITCI
91
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$6.01M 0.22%
150,000
-77,164
-34% -$2.52M
IONS icon
92
Ionis Pharmaceuticals
IONS
$7.85B
$5.94M 0.21%
147,000
+48,800
+50% +$2.53M
BLUE
93
CALL
DELISTED
bluebird bio
BLUE
$5.77M 0.21%
+5,203
New +$9.49M
MDT icon
94
CALL
Medtronic
MDT
$120B
$5.54M 0.2%
+82,700
New +$6.09M
HRTX icon
95
Heron Therapeutics
HRTX
$59.6M
$5.34M 0.19%
219,000
-217,970
-50% -$7.26M
ADYX
96
DELISTED
Adynxx Inc
ADYX
$5.23M 0.19%
27,500
– –
ICLR icon
97
Icon
ICLR
$13.3B
$5.11M 0.18%
+72,000
New +$5.42M
VTRS icon
98
CALL
Viatris
VTRS
$19.1B
$4.75M 0.17%
118,000
-54,400
-32% -$3.03M
AGN.PRA
99
DELISTED
Allergan plc
AGN.PRA
$4.72M 0.17%
5,000
– –
MNK
100
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$4.66M 0.17%
+72,800
New +$7.21M
2 3
4
5 6

Similar funds

EST
EA Series Trust Newtown Square, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2015 Portfolio in Review

As of Q3 2015, Tekla Capital Management held 179 positions worth $2.78B, up 0.66% from $2.76B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Tekla Capital Management deployed $336M of net new capital in Q3 2015, opening 61 new positions and adding to 32 existing holdings. Its largest new stake was UnitedHealth: 312,600 shares worth $36.3M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 87% a quarter earlier, followed by Miscellaneous and Real Estate.

On the sell side, the largest reduction was Amgen, an estimated $27.7M trimmed.

  • Tekla Capital Management's largest Q3 2015 buy was UnitedHealth: 312,600 shares worth $36.3M.
  • Tekla Capital Management added most to Biogen in Q3 2015, an estimated $37.6M increase.
  • Tekla Capital Management's biggest Q3 2015 reduction was Amgen, cutting an estimated $27.7M.
  • Tekla Capital Management fully exited CATAMARAN CORP COM STK (CDA) in Q3 2015, selling an estimated $26.5M.
  • Tekla Capital Management's ten largest holdings make up 42% of its $2.78B portfolio in Q3 2015.
  • Tekla Capital Management opened 61 new positions and closed 19 in Q3 2015.
  • Tekla Capital Management's portfolio value rose 0.66% quarter-over-quarter to $2.78B.

Based on Tekla Capital Management's 13F filing for Q3 2015, filed 13 Nov 2015.